Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-TCR Summit Europe 2021 | Exciting advances in CAR-T and TCR research

David Gilham, PhD, Celyad Oncology, Mont-Saint-Guibert, Belgium, offers some of his highlights from the CAR-TCR Summit Europe 2021. He describes CYAD-211, a short hairpin RNA (shRNA)-based B-cell maturation antigen (BCMA)-targeting allogeneic chimeric antigen receptor (CAR) T candidate, which is being investigated in ongoing clinical trials for the treatment of patients with relapsed or refractory multiple myeloma (r/r MM). He also discusses exciting developments presented at the meeting, included advances in the understanding of the mechanisms of action of CD19-targeting CAR T-cell therapies, as well as advances in T-cell receptor (TCR) platforms under investigation. This interview took place during the CAR-TCR Summit Europe 2021.